Cytek Biosciences Inc（CTKB）財務資料CTKBCytek Biosciences Inc

Cytek Biosciences, Inc. (CTKB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Biotechnology, pharmaceutical, distributor and CRO, accounting for 60.3% of total sales, equivalent to $29.02M. Another important revenue stream is Academia and government. Understanding this composition is critical for investors evaluating how CTKB navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Cytek Biosciences, Inc. maintains a gross margin of 58.87%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.68%, while the net margin is -25.26%. These profitability ratios, combined with a Return on Equity (ROE) of -23.04%, provide a clear picture of how effectively CTKB converts its operational activities into shareholder value.

In the context of the broader market, CTKB competes directly with industry leaders such as MLAB and MDXG. With a market capitalization of $696.71M, it holds a significant position in the sector. When comparing efficiency, CTKB's gross margin of 58.87% stands against MLAB's 64.87% and MDXG's 68.50%. Such benchmarking helps identify whether Cytek Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Cytek's revenue for Q2 2026 was $48.14 million, with a gross margin of 58.87%. However, the company has been reporting consistent net losses, with a net income of -12.16 million in Q2 2026 and a negative net margin of -25.26%.